Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population

NCT ID: NCT03486743

Last Updated: 2020-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

437 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-15

Study Completion Date

2019-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preliminary data from our work with teen mothers suggest that many women would benefit from contraception but do not actually make visits nor initiate conversations regarding contraception unless the subject is raised by the clinician. Those coming for primary care visits discuss their conditions and care with family and friends, spreading health care information. A substantial proportion of citizens obtain their health information from friends, family, internet, social media and other non-clinicians. Thus, educating women, even when not coming expressly for contraceptive services, increases more accurate health information throughout their communities and actually identifies fertility needs, ultimately increasing use of contraception.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Seven clinical family medicine health centers will be included in the study. Target participants are women aged 18-45 years old. These clinical sites are community-based health centers within the University of Pittsburgh Medical Center (UPMC) system in greater Pittsburgh that serve as teaching sites for medical, pharmacy and social work students enrolled at the University of Pittsburgh and/or UPMC Family Medicine or clinical pharmacy residents. In 2015, these sites served nearly 32,000 patients of whom more than 60% are women. More than 10,000 females were in the target age group of 18-45 years old and more than half were from underrepresented minority groups. The patients served by these family health centers are diverse across race and ethnicity, family income level, neighborhoods and literacy level . All are managed and documented in the EpicCare electronic medical record system.

We target women aged 18-45 years because this study is designed to assess cultural beliefs regarding Long Acting Reversible Contraception (LARC) in women in general and not specifically those who are seeking contraception. Preliminary data from our work with teen mothers suggest that many women would benefit from contraception but do not actually make visits nor initiate conversations regarding contraception unless the subject is raised by the clinician. Those coming for primary care visits discuss their conditions and care with family and friends, spreading health care information. A substantial proportion of citizens obtain their health information from friends, family, and other non-clinicians. Thus, educating women, even when not coming expressly for contraceptive services, increases more accurate health information throughout their communities and actually identifies fertility needs, ultimately increasing use of contraception.

Seven clinical sites (UPMC Family Health Centers) will be included in the study. The best and low-cost recruitment strategy will be to reach women aged 18-45 years who attend our health centers for womens' health services. Our project team will engage personnel in these health centers and inform them about the proposed study. We will place postcards at the check-in desk, and encourage target women to take a postcards and follow up with the research team if they are interested in participating.

Participants of the project will be identified by the nurses performing initial intakes of patients presenting for care - also called "rooming" the patient. Research assistants will also try to approach patients in the waiting room in the case they were not able to approach them in the examination rooms. Those recruited from each site will be stratified to one of two groups - one for those identifying contraception as the focus of their physician visit and the other group for those seeking other women's health services at the physician visit.

In an effort to improve recruitment, we will work with the clinical staff to understand particular hours during which potential participants are likely to present to the clinic. Flyers will be placed in all seven health centers, In addition, a research assistant will be on site at projected high utilization times. The research assistants will provide information on the study to clinical staff, and will be available to distribute study postcards and answer questions from potential participants. Interested young women will meet with the research assistants for eligibility determination, completion of Institutional Review Board (IRB) consents, and enrollment in the study. Incentives will be provided to all participants enrolled in the study.

Three health centers received a substantial volume of the female patients who were in the specific age group being targeted in the study will be invited to comprise the intervention arm. The rest of the health centers will form the control arm.

It is important that the survey questions reflect the target population's perspectives of using LARC or any contraceptive devices. Both the demographic and cultural surveys will be distributed to women, 18-45 years of age, seeking womens' health services in participating family health centers who expressed interest in the study. Surveys will be completed on a tablet provided by a research assistant or on the participant's own mobile device or personal computer. Participants will be given the option to complete the surveys at the family health center or elsewhere at another time. Women participating in the focus groups are ineligible for participation in the survey.

Participants in the intervention arm will complete both the demographic and the cultural survey. After participating in the survey, the participants in the intervention arm will be asked to watch an educational video on LARC to be taped by a professional team in the Center for Instructional Development \& Distance Education (CIDDE) at the University of Pittsburgh. In this video, a family physician skilled in contraceptive education will provide useful and easily understandable information on LARC. The video will include, but is not limited to, the following key topics:

* What types of LARC are available?
* How each LARC method works?
* How and where the LARC method is inserted?
* How long LARC works?
* What are the risks and benefits of each LARC method?
* Can LARC be removed at any time, how it is removed and are there any potential side effects such as slow return of fertility?

A short survey will be distributed to all participants who watched the video in the intervention arm. The survey will include questions on LARC that were similar to the questions included in the survey before watching the video. We will then evaluate both surveys before and after watching the video. The participants will be given the option to complete all study activities at the family health center or elsewhere at another time.

With improved understanding regarding how LARC is perceived through data obtained from the cultural assessment, more targeted education for both clinicians, clinical staff, and patients of childbearing age is possible. Therefore, if the cultural assessment (via focus group feedback and/or survey responses) reveals that patients fear permanent sterilization or believe use of LARC violates religious mores, patient education can be modified to address their specific concerns. These study results may lead to further investigation to change approaches to the target population and allow us to provide better clinical care

Following (1) assessment of historical data on LARC use in the seven health centers prior to this study; (2) perceptions elicited from the focus groups(from phase one of the study); (3) results of the group completing both demographic and cultural surveys; and (4) results of the group completing demographic and cultural surveys and watching the informational video, the final step involves assessing changes in LARC use. Electronic medical records and billing data from the seven health centers will be reviewed to determine LARC utilization across the targeted population served by these health centers and the impact of the interventions on LARC usage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

different sites of participant recruitment will be randomized between the use of an informational video during the survey process and no video. The primary focus of the study is the survey that is designed to collect information about cultural perspectives on LARC in the participants.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention arm

Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.

Group Type EXPERIMENTAL

Educational video on LARC

Intervention Type BEHAVIORAL

Participants will watch a short educational video on long acting reversible contraceptive or LARC

Control arm

Participants in the intervention arm will only be asked to complete a survey.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Educational video on LARC

Participants will watch a short educational video on long acting reversible contraceptive or LARC

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between age of 18 and 45
* Not currently pregnant
* Did not participate in phase I of the study

Exclusion Criteria

* Below 18 years or above 45
* Currently pregnant
* Participated in Phase I of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeannette E. South-Paul

Andrew W. Mathieson UPMC Professor and Chair

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeannette E. South-Paul, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Latterman Family Health Center

McKeesport, Pennsylvania, United States

Site Status

New Kensington Family Health Center

New Kensington, Pennsylvania, United States

Site Status

UPMC Matilda Theiss Health Center

Pittsburgh, Pennsylvania, United States

Site Status

Squirrel Hill Family Practice

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Bloomfiled-Garfield FHC

Pittsburgh, Pennsylvania, United States

Site Status

Lawrenceville Family Health Center

Pittsburgh, Pennsylvania, United States

Site Status

Shadyside Family Health Center

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011 Nov;84(5):493-8. doi: 10.1016/j.contraception.2011.03.001. Epub 2011 Apr 27.

Reference Type BACKGROUND
PMID: 22018123 (View on PubMed)

Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010 Aug;203(2):115.e1-7. doi: 10.1016/j.ajog.2010.04.017. Epub 2010 Jun 11.

Reference Type BACKGROUND
PMID: 20541171 (View on PubMed)

Romero L, Pazol K, Warner L, Gavin L, Moskosky S, Besera G, Loyola Briceno AC, Jatlaoui T, Barfield W; Centers for Disease Control and Prevention (CDC). Vital signs: trends in use of long-acting reversible contraception among teens aged 15-19 years seeking contraceptive services-United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2015 Apr 10;64(13):363-9.

Reference Type BACKGROUND
PMID: 25856258 (View on PubMed)

Harper CC, Blum M, de Bocanegra HT, Darney PD, Speidel JJ, Policar M, Drey EA. Challenges in translating evidence to practice: the provision of intrauterine contraception. Obstet Gynecol. 2008 Jun;111(6):1359-69. doi: 10.1097/AOG.0b013e318173fd83.

Reference Type BACKGROUND
PMID: 18515520 (View on PubMed)

Stanwood NL, Bradley KA. Young pregnant women's knowledge of modern intrauterine devices. Obstet Gynecol. 2006 Dec;108(6):1417-22. doi: 10.1097/01.AOG.0000245447.56585.a0.

Reference Type BACKGROUND
PMID: 17138775 (View on PubMed)

Whitaker AK, Sisco KM, Tomlinson AN, Dude AM, Martins SL. Use of the intrauterine device among adolescent and young adult women in the United States from 2002 to 2010. J Adolesc Health. 2013 Sep;53(3):401-6. doi: 10.1016/j.jadohealth.2013.04.011. Epub 2013 Jun 12.

Reference Type BACKGROUND
PMID: 23763968 (View on PubMed)

Damle LF, Gohari AC, McEvoy AK, Desale SY, Gomez-Lobo V. Early initiation of postpartum contraception: does it decrease rapid repeat pregnancy in adolescents? J Pediatr Adolesc Gynecol. 2015 Feb;28(1):57-62. doi: 10.1016/j.jpag.2014.04.005. Epub 2014 May 5.

Reference Type BACKGROUND
PMID: 25555302 (View on PubMed)

Okpo E, Allerton L, Brechin S. 'But you can't reverse a hysterectomy!' Perceptions of long acting reversible contraception (LARC) among young women aged 16-24 years: a qualitative study. Public Health. 2014 Oct;128(10):934-9. doi: 10.1016/j.puhe.2014.08.012. Epub 2014 Oct 22.

Reference Type BACKGROUND
PMID: 25369357 (View on PubMed)

Greenberg KB, Makino KK, Coles MS. Factors associated with provision of long-acting reversible contraception among adolescent health care providers. J Adolesc Health. 2013 Mar;52(3):372-4. doi: 10.1016/j.jadohealth.2012.11.003.

Reference Type BACKGROUND
PMID: 23427785 (View on PubMed)

Rubin SE, Davis K, McKee MD. New york city physicians' views of providing long-acting reversible contraception to adolescents. Ann Fam Med. 2013 Mar-Apr;11(2):130-6. doi: 10.1370/afm.1450.

Reference Type BACKGROUND
PMID: 23508599 (View on PubMed)

Russo JA, Miller E, Gold MA. Myths and misconceptions about long-acting reversible contraception (LARC). J Adolesc Health. 2013 Apr;52(4 Suppl):S14-21. doi: 10.1016/j.jadohealth.2013.02.003.

Reference Type BACKGROUND
PMID: 23535052 (View on PubMed)

Roncancio AM, Ward KK, Berenson AB. The use of effective contraception among young Hispanic women: the role of acculturation. J Pediatr Adolesc Gynecol. 2012 Feb;25(1):35-8. doi: 10.1016/j.jpag.2011.08.008. Epub 2011 Nov 3.

Reference Type BACKGROUND
PMID: 22051784 (View on PubMed)

Doescher MP, Saver BG, Franks P, Fiscella K. Racial and ethnic disparities in perceptions of physician style and trust. Arch Fam Med. 2000 Nov-Dec;9(10):1156-63. doi: 10.1001/archfami.9.10.1156.

Reference Type BACKGROUND
PMID: 11115223 (View on PubMed)

Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath JK, Daviaud I, Guiomar R, Necula G, Bella A, O'Donnell J, Gluchowska M, Ciancio BC, Nicoll A, Moren A. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013 Jan 31;18(5):20390. doi: 10.2807/ese.18.05.20390-en.

Reference Type BACKGROUND
PMID: 23399425 (View on PubMed)

deBorja L, Lin C, Maier J, South-Paul JE, Lewis E. Assessment of Cultural Acceptability of Long-Acting Reversible Contraception in a Diverse, Urban Population: Phase II of a Two Phase Study.North American Primary Care Research Group Annual Meeting - NOV 2018 / Chicago, IL (https://www.napcrg.org/conferences/46/sessions/23230)

Reference Type RESULT

deBorja L. The Role of Social Influence and Usage of Long-Acting Reversible Contraception: Analysis of Survey Responses. North American Primary Care Research Group Annual Meeting - Toronto, ON / NOV. 2019. (https://www.napcrg.org/conferences/2001/sessions/794)

Reference Type RESULT

Lin CJ, Maier J, Nwankwo C, Burley C, deBorja L, Aaraj YA, Lewis E, Rhem M, Nowalk MP, South-Paul J. Awareness and Use of Contraceptive Methods and Perceptions of Long-Acting Reversible Contraception Among White and Non-White Women. J Womens Health (Larchmt). 2021 Sep;30(9):1313-1320. doi: 10.1089/jwh.2020.8642. Epub 2020 Dec 9.

Reference Type DERIVED
PMID: 33297819 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Merck IIS# 55000 phase II

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Inpatient Adolescent Contraception
NCT04423068 COMPLETED EARLY_PHASE1
Long-Acting Reversible Contraception
NCT01299116 COMPLETED PHASE4